Best Stocks, ETFs, and Catalysts to Watch in 2026
The SPDR S&P Biotech ETF (XBI) returned roughly 40% over the trailing year as of April 2026 — more than double the S&P 500. This guide walks you through why 2026 is the most favorable backdrop for the sector in years, how to buy in, and how to manage the risk.
The honest framing upfront: biotech investing is high variance. Even diversified biotech ETFs swing 30%+ in single years. Individual clinical-stage names regularly drop 80%+ on a single failed trial. Position-size accordingly.
This biotech investment guide covers everything: the three ways to actually buy in (individual stocks, ETFs, biotech-focused mutual funds), the major sub-themes (oncology, GLP-1 obesity drugs, gene editing, mRNA, rare diseases), how to evaluate a clinical-stage biotech, and how to read an FDA PDUFA calendar. By the end you'll know which ETF fits your goals (XBI vs IBB vs FBT vs SBIO vs ARKG) and how much of your portfolio biotech should take up. The wider asset-class context lives in the Best Investments for 2026 pillar.
What Biotech Actually Is (and Why It's Different from Pharma)
Biotech companies develop therapies using biological systems — recombinant DNA, cell therapy, gene editing, mRNA platforms, monoclonal antibodies. Pharma companies historically focused on small-molecule drugs synthesized chemically. The line has blurred, but the distinction still matters:
- Pharma (Pfizer, Merck, J&J pharmaceutical division) — large, profitable, dividend-paying, slow-growing, P/Es around 12–18
- Biotech (everything from $200M clinical‑stage names to large‑cap leaders like Vertex and Regeneron) — higher growth, much higher volatility, often unprofitable in early years
A typical drug development cycle runs 10–15 years from discovery to FDA approval, with success rates around 10% from Phase 1 to approval. The companies that make it generate enormous returns; those that fail go to zero. That binary outcome explains why diversification matters more in biotech than almost any other sector.
Why 2026 Is the Best Biotech Setup in Years
1. Falling Interest Rates
The Federal Reserve cut rates three times in 2025 with another 150 basis points projected for 2026. This matters enormously for biotech because most clinical‑stage companies burn cash for years before generating revenue. Lower borrowing costs make secondary offerings less dilutive, reduce the discount rate on future cash flows, and enable mid‑cap debt financing. The 2022‑2023 rate hikes crushed the sector in reverse — XBI dropped over 50% from its February 2021 peak.
2. The Pharma Patent Cliff and M&A Wave
Roughly $300 billion in annual pharma revenue faces patent expiration between 2025 and 2030 — Keytruda (~$25B annually), Eliquis, Stelara, Humira (already off‑patent). Pharma companies need to replace this revenue, and acquiring biotech with late‑stage assets is faster than internal R&D. M&A activity accelerated through late 2025 with a string of $5–15 billion deals. Bank of America Research recently called biotech valuations "acceptable, offering room for upside if sentiment improves."
3. AI in Drug Discovery Producing Real Candidates
Companies like Recursion (RXRX), Schrödinger (SDGR), and AbCellera are using machine learning to compress preclinical timelines and improve hit rates. The first AI‑discovered drugs are now in Phase 2 trials. The ability to identify promising compounds 60–80% faster changes the economics for both biotech startups and big‑pharma acquirers.
4. Valuations at Sector Lows
The biotech sector P/E currently trades slightly below the S&P 500 — historically rare. Portfolio managers tracking the space note that company valuations sit at roughly a 15% discount to broader markets on forward P/E, with secular demand intact for oncology, obesity, and chronic disease treatments. Cheap valuations plus improving fundamentals plus favorable rates is a setup that doesn't show up often.
The honest caveat: every previous biotech rally has been followed by a brutal correction. The 2014 rally peaked into a 50% drawdown; the 2021 peak preceded a 60% sector decline. Don't confuse strong recent returns with low risk.
Three Ways to Invest in Biotech
Option 1: Biotech ETFs (Recommended for Most Investors) — Diversification across hundreds of names spreads single‑company risk and protects you from the binary clinical‑trial outcomes that wreck individual stock picks.
Option 2: Individual Biotech Stocks — Higher upside, much higher risk. Reasonable only for investors who can read a clinical trial readout and who limit each position to 1–2% of portfolio.
Option 3: Biotech‑Focused Mutual Funds — Active management with sector specialists. T. Rowe Price Health Sciences Fund (PRHSX), Fidelity Select Biotechnology (FBIOX), and Vanguard Health Care Fund (VGHCX) are the household names. Higher expense ratios than ETFs (typically 0.70–0.90%) but managers with deep sector knowledge. Worth considering if you're already a Fidelity/T. Rowe customer.
Best Biotech ETFs for 2026 Compared
| ETF | Issuer | Holdings | Weighting | Expense Ratio | Trailing 1‑Yr Return (Apr 2026) | Best For |
|---|---|---|---|---|---|---|
| XBI | SPDR (State Street) | ~150 | Equal‑weight (modified) | 0.35% | ~40% | Small/mid‑cap M&A upside |
| IBB | iShares (BlackRock) | ~250 | Market‑cap weighted | 0.45% | ~34% | Large‑cap stability |
| FBT | First Trust | ~30 | Equal‑weight | 0.55% | ~29% | Concentrated equal‑weight |
| SBIO | ALPS | ~90 | Modified equal‑weight | 0.50% | Variable | Phase 2/3 clinical‑stage focus |
| ARKG | ARK Invest | 40-60 | Active | 0.75% | Variable | Gene editing thesis |
XBI vs IBB: The Decision Most Investors Face
XBI is equal‑weighted — small and mid‑cap names drive returns, capturing more M&A upside. IBB is market‑cap weighted — Vertex, Amgen, Regeneron, Gilead dominate; more stable but less explosive upside. Goldman Sachs biotech analyst Salveen Richter expects the biotech recovery to continue through 2026, citing improving fundamentals and a more constructive regulatory environment. If she's right and small/mid‑cap biotech leads, XBI outperforms IBB. For most investors targeting biotech as a 5–10% satellite, XBI is the cleaner pick. For risk‑averse investors, IBB.
FBT, SBIO, and ARKG — FBT holds 30 equal‑weight stocks. SBIO focuses on Phase 2/3 small/mid‑caps. ARKG is Cathie Wood's actively managed gene‑editing fund (highest expense ratio, most volatile). The full breakdown is in our best biotech ETFs for 2026 comparison.
The Sub‑Themes Driving Biotech in 2026
Oncology
The largest therapeutic area. Leaders: Merck (Keytruda, loses key patents in 2028), Bristol‑Myers Squibb (Opdivo, CAR‑T), Gilead (Trodelvy), Regeneron (Libtayo, bispecifics). For pure‑play exposure, the Tema Oncology ETF (CANC) launched in 2024.
GLP‑1 Obesity Drugs
A $50+ billion annual market projected to reach $150 billion by 2030. Key names: Eli Lilly (Mounjaro, Zepbound, oral GLP‑1), Novo Nordisk (Ozempic, Wegovy), Amgen (MariTide), Viking Therapeutics (VK2735), Structure Therapeutics (GPCR), Roche (CT‑388). Risks: compounding pharmacies, insurance battles, side‑effect data. Full breakdown in our investing in GLP‑1 and obesity drug stocks guide.
Gene Editing
CRISPR‑based therapies got their first FDA approval in late 2023 (Casgevy for sickle cell). Pure‑plays: CRISPR Therapeutics (CRSP), Editas Medicine (EDIT), Beam Therapeutics (BEAM), Verve Therapeutics (VERV — acquired by Eli Lilly in 2025), Intellia Therapeutics (NTLA). ARKG provides diversified exposure.
mRNA Platforms
Beyond COVID vaccines: Moderna (personalized cancer vaccine with Merck, CMV, RSV) and BioNTech (oncology pipeline). Both have struggled since COVID revenue collapsed — the bet is whether the broader mRNA platform produces another commercial success.
Rare Diseases
Vertex Pharmaceuticals (cystic fibrosis, sickle cell, pain pipeline), Alnylam Pharmaceuticals (RNAi), BioMarin (enzyme replacement), Ionis Pharmaceuticals (antisense oligonucleotides). Vertex is the closest thing biotech has to a "blue chip."
Top Individual Biotech Stocks to Watch in 2026
| Ticker | Company | What They Make | Why It Matters in 2026 |
|---|---|---|---|
| LLY | Eli Lilly | Mounjaro, Zepbound, Alzheimer's pipeline | GLP-1 dominance, oral GLP-1 catalyst |
| NVO | Novo Nordisk | Ozempic, Wegovy | Manufacturing scale‑up, next‑gen pipeline |
| VRTX | Vertex Pharmaceuticals | Cystic fibrosis franchise, sickle cell | Pain pipeline (suzetrigine), broadest moat |
| REGN | Regeneron | Eylea, Libtayo, antibody platform | Eylea HD launch, oncology bispecifics |
| AMGN | Amgen | Repatha, Otezla, MariTide | MariTide obesity readouts |
| GILD | Gilead Sciences | HIV franchise, Trodelvy, lenacapavir | HIV PrEP launch, oncology rebuild |
| MRNA | Moderna | mRNA platform | Cancer vaccine readouts with Merck |
| BNTX | BioNTech | mRNA oncology pipeline | Cash position, late‑stage cancer trials |
| AXSM | Axsome Therapeutics | CNS drugs (Auvelity, Sunosi) | Alzheimer's agitation PDUFA April 2026 |
| CRSP | CRISPR Therapeutics | Casgevy, in vivo editing pipeline | Casgevy commercial ramp, in vivo readouts |
This is the watchlist most biotech‑focused funds are working from. Each of these has been part of major institutional positions through 2025‑2026. Full profiles in our top 10 biotech stocks to watch in 2026 breakdown.
How to Read an FDA PDUFA Calendar
The PDUFA date (Prescription Drug User Fee Act) is the deadline by which the FDA must decide on a drug application — the single most important catalyst on any biotech investor's calendar.
How It Works: A company submits an NDA or BLA → FDA assigns a PDUFA date (10 months standard, 6 priority) → by that date the FDA approves, rejects (Complete Response Letter), or extends the review. The stock typically moves 20–50% on the decision.
Where to Track: FDA.gov (official), BioPharma Catalyst (free retail tracker), EvaluatePharma (institutional, paid), company IR pages.
How to Position: Most retail investors lose money trading these. Safer approaches: buy the diversified ETF (XBI, IBB) to capture sector sentiment; if buying individual names, position‑size for total loss (never more than 1% of portfolio in a single stock ahead of a PDUFA).
How to Evaluate a Clinical‑Stage Biotech
1. Cash Runway — Cash ÷ quarterly burn. Under 12 months of runway means imminent dilution. Pull from the most recent 10‑Q on SEC EDGAR.
2. Pipeline Depth — Multiple programs in Phase 2 or later, across at least two therapeutic areas, preferably a platform technology (mRNA, CRISPR, ADC).
3. Phase 2 and Phase 3 Readouts — Read the trial design: primary endpoint, statistical power, comparator arm (placebo vs standard of care), patient population.
4. Partnership and Licensing Deals — A big‑pharma partnership validates the asset and provides cash. Watch for Eli Lilly, Merck, AbbVie, Bristol/J&J licensing.
Run Your Position Size: Biotech Risk‑Adjusted Position Sizer
Plug in your total portfolio size, risk tolerance, and position type (ETF or individual stock). The calculator outputs a recommended dollar allocation that keeps your maximum drawdown contribution within reasonable bounds.
Open the Biotech Risk‑Adjusted Position Sizer →A worked example: $100,000 portfolio, balanced risk tolerance. Recommended biotech allocation = 5–7% total, split as roughly 4% in XBI (broad sector exposure) and 1–2% in 1–2 individual large‑cap names like LLY or VRTX. Maximum exposure to any single clinical‑stage name capped at 1%.
The Risk Framework You Can't Skip
- Concentrated bets on single Phase 3 readouts. A 50% allocation to one clinical‑stage biotech ahead of a binary readout is gambling.
- Ignoring cash runway. Buying a biotech with 6 months of cash means you're underwriting a dilutive offering.
- Confusing recent returns with sustainable returns. XBI's 40% trailing year doesn't mean another 40% is coming.
- Buying after a 50%+ rally without a thesis update. If the only reason is "it went up," you're chasing momentum.
- Treating biotech ETFs as low‑risk. Even XBI dropped 50%+ from its 2021 peak.
- Position sizing as if biotech behaves like the S&P 500. A 30% drawdown in biotech in a single year is normal. Plan for it.